Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...
The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients ...
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...
Magna relies heavily on a handful of automakers; its top six customers accounted for 73% of total 2024 revenue. Asian automakers can be hard to gain share with.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results